We are focusing on potential marketability of anti-fungi drug.
In recent years, patients suffered by mycosis are increasing by opportunistic infection due to immunodeficiency by aging, cancer and/or AIDS. The market size of anti-fungi drug is reaching to 150 billion dollar at the whole world. The number of patients is increasing every year, and when patients in developing nations are included, the potential market is extremely huge. Furthermore, the number of patients will be increasing far from our imagination due to the development of aging.
On the other hand, aniti-fugi drug with new chemical framework has not been supplied for the last few decades. The most of the new anti-fungi drugs are azole-based synthesized ones that have been put into the market.
Another problem is appearance of resistant fungi due to long time using of azole-based and/or candin-based drugs, which is becoming a serious social problem. It's the current state that amphotericin B found in 1955 at an early development stage of antifungal drug, is still used because of no appearance of resistant fungi. Under the current situations, doctors and patients are seriously in need of a brand new type of antifungal drugs.
Therefore, an appearance of antifungal drug with oxaziridine framework that we found in this study, is epoch-making, and will open a new door to antifungal drugs following azole-based and candin-based ones.
We believe that it's very important to be able to offer new oxaziridine –based antifungal drugs in the current situation where the market is expanding and many patients are waiting with open arms.
Morita Iwami, Ph.D.
石見 盛太 （工学博士）